Q3 FY2026
Filed Nov 5, 2026Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance – Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year
Product revenues, net increased 3% year-over-year to a record $216.3 million, led by JORNAY PM growth and the first full quarter of AZSTARYS sales under Collegium ownership, but the pain portfolio declined 18%, GAAP and adjusted earnings declined, and adjusted EBITDA declined 9%.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Product revenues, net - three months ended September 30, 2026GAAP | $216.3M | – | 3% increase |
| Product revenues, net - nine months ended September 30, 2026GAAP | $609.7M | – | – |
| Cost of product revenues excluding intangible asset amortization - three months ended September 30, 2026GAAP | $35.58M | – | – |
| Intangible asset amortization in cost of product revenues - three months ended September 30, 2026GAAP | $55.35M | – | – |
| Total cost of product revenues - three months ended September 30, 2026GAAP | $90.92M | – | – |
| Gross profit - three months ended September 30, 2026GAAP | $125.4M | – | – |
| GAAP operating expenses - three months ended September 30, 2026GAAP | $96.7M | – | 44% increase |
| Adjusted operating expenses - three months ended September 30, 2026non-GAAP | $69.4M | – | 25% increase |
| Income from operations - three months ended September 30, 2026GAAP | $28.72M | – | – |
| Net income - three months ended September 30, 2026GAAP | $21.8M | – | – |
| GAAP earnings per share, basic - three months ended September 30, 2026GAAP | $0.69 | – | – |
| GAAP earnings per share, diluted - three months ended September 30, 2026GAAP | $0.60 | – | – |
| Adjusted net income - three months ended September 30, 2026non-GAAP | $75.2M | – | – |
| Adjusted earnings per share - three months ended September 30, 2026non-GAAP | $1.96 | – | – |
| Adjusted EBITDA - three months ended September 30, 2026non-GAAP | $121.6M | – | 9% decrease |
| Gross profit - nine months ended September 30, 2026GAAP | $353.0M | – | – |
| GAAP operating expenses - nine months ended September 30, 2026GAAP | $289.6M | – | – |
| Income from operations - nine months ended September 30, 2026GAAP | $63.32M | – | – |
| Net income - nine months ended September 30, 2026GAAP | $21.20M | – | – |
| GAAP earnings per share, diluted - nine months ended September 30, 2026GAAP | $0.64 | – | – |
| Adjusted net income - nine months ended September 30, 2026non-GAAP | $219.8M | – | – |
| Adjusted earnings per share - nine months ended September 30, 2026non-GAAP | $5.63 | – | – |
| Adjusted EBITDA - nine months ended September 30, 2026non-GAAP | $339.3M | – | – |
| Cash from operations - three months ended September 30, 2026GAAP | $86.5M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| JORNAY PMJORNAY PM prescriptions grew 16% year-over-year and nearly 33,000 healthcare providers wrote JORNAY PM prescriptions, up 19% year-over-year. | $51.9M | – | 24% |
| AZSTARYSThis was the first full quarter of sales under Collegium ownership; prescriptions grew nearly 2% compared to the quarter ended September 30, 2025. | $26.5M | – | – |
| Pain portfolioThe portfolio includes Belbuca, Xtampza ER and the Nucynta Franchise. | $138M | – | down 18% |
| BelbucaBelbuca was the largest reported pain-portfolio product by quarterly net revenue. | $57.7M | – | down 1% |
| Xtampza ERXtampza ER net revenue declined year-over-year. | $45.8M | – | down 9% |
| Nucynta FranchiseRevenue included $4.2 million from Hikma Pharmaceuticals USA Inc. for the sale of authorized generic versions of Nucynta and Nucynta ER. | $30.8M | – | down 44% |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Full-year 2026 outlook
- RevenueProduct Revenues, Net $825 to $855 million
- NoteJORNAY PM Revenue, Net $190 to $200 million
- NoteAZSTARYS Revenue, Net $65 to $75 million
- NoteAdjusted EBITDA $445 to $470 million
Capital returns
- Announced a $50 million accelerated share repurchase program in Q3 2026.
- The final settlement of the accelerated share repurchase program is expected to be completed in the fourth quarter of 2026.
What drove it
- Expanded commercial efforts supported ADHD demand heading into the back-to-school season.
- JORNAY PM reached record revenues, prescriptions and prescriber adoption.
- AZSTARYS generated its first full quarter of sales under Collegium ownership.
- ADHD franchise revenue contributed more than 36% of total revenue.
- The company reaffirmed full-year 2026 guidance for Product Revenues, Net, JORNAY PM Revenue, Net, AZSTARYS Revenue, Net and Adjusted EBITDA.
Concerns
- Pain portfolio net revenues were down 18% year-over-year, including a 44% decline in Nucynta Franchise net revenue.
- GAAP operating expenses increased 44% year-over-year and adjusted operating expenses increased 25% year-over-year.
- GAAP net income, adjusted net income and adjusted EBITDA were lower than in the 2025 Quarter.
- The company identified risks related to realizing anticipated benefits of the AZSTARYS acquisition, commercialization, competition, reimbursement, supply, litigation and regulatory compliance.
What to watch
- Completion of the $50 million accelerated share repurchase program in the fourth quarter of 2026.
- JORNAY PM prescription and prescriber growth following expanded commercial efforts.
- AZSTARYS revenue and prescription performance following its first full quarter under Collegium ownership.
- Pain portfolio performance, particularly the Nucynta Franchise.
- Delivery against reaffirmed full-year 2026 Product Revenues, Net and adjusted EBITDA guidance.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities were $144.8 million at September 30, 2026.
- Cash and cash equivalents were $144,797 (in thousands) at September 30, 2026, compared to $231,252 (in thousands) at December 31, 2025.
- Marketable securities were — at September 30, 2026, compared to $155,427 (in thousands) at December 31, 2025.
- Term notes payable were $842,507 (in thousands) at September 30, 2026, compared to $571,112 (in thousands) at December 31, 2025.
- Convertible senior notes were $238,996 (in thousands) at September 30, 2026, compared to $238,213 (in thousands) at December 31, 2025.
- Accounts receivable, net were $310,785 (in thousands) at September 30, 2026, compared to $211,328 (in thousands) at December 31, 2025.
- Inventory was $88,202 (in thousands) at September 30, 2026, compared to $40,912 (in thousands) at December 31, 2025.
- Total assets were $2,095,936 (in thousands) at September 30, 2026, compared to $1,656,834 (in thousands) at December 31, 2025.
- Shareholders’ equity was $296,437 (in thousands) at September 30, 2026, compared to $301,675 (in thousands) at December 31, 2025.
Analysis
Collegium reported record quarterly Product revenues, net of $216.3 million, up 3% year-over-year from $209.4 million. The growth profile was concentrated in ADHD: JORNAY PM generated $51.9 million, up 24%, while AZSTARYS contributed $26.5 million in its first full quarter under Collegium ownership. Management reported that the ADHD franchise contributed more than 36% of total revenue.
The legacy pain portfolio remained a material offset. Pain portfolio net revenues were $138.0 million, down 18% year-over-year. Belbuca declined 1% to $57.7 million and Xtampza ER declined 9% to $45.8 million, while the Nucynta Franchise declined 44% to $30.8 million. The Nucynta result included $4.2 million from Hikma for authorized generic versions of Nucynta and Nucynta ER.
Profitability declined despite revenue growth. Gross profit was $125,418 (in thousands), versus $129,171 (in thousands) in the prior-year quarter. GAAP operating expenses increased 44% to $96.7 million, and adjusted operating expenses increased 25% to $69.4 million. GAAP net income was $21.8 million, compared with $31.5 million, while adjusted net income was $75.2 million, compared with $87.3 million. Adjusted EBITDA declined 9% to $121.6 million.
Cash from operations was $86.5 million for the quarter, and cash, cash equivalents and marketable securities were $144.8 million at quarter-end. Term notes payable were $842,507 (in thousands), versus $571,112 (in thousands) at December 31, 2025. The company announced a $50 million accelerated share repurchase program in Q3 2026 and expects final settlement in the fourth quarter of 2026.
Management reaffirmed its full-year 2026 outlook: Product Revenues, Net of $825 to $855 million, JORNAY PM Revenue, Net of $190 to $200 million, AZSTARYS Revenue, Net of $65 to $75 million, and adjusted EBITDA of $445 to $470 million. The principal reported operating markers are the sustainability of JORNAY PM growth, AZSTARYS prescription momentum, and the degree to which ADHD growth can offset pain-portfolio declines and higher operating expenses.
Management, verbatim
We continued to see strong demand across our ADHD portfolio, supported by expanded commercial efforts heading into the back-to-school season. JORNAY PM reached record revenues, prescriptions and prescriber adoption, with quarterly net revenue growing 24% year-over-year.
Vikram Karnani, President and Chief Executive Officer
Additionally, in the first full quarter of Collegium’s ownership of AZSTARYS, revenues exceeded $26.5 million supported by nearly 2% prescription growth year-over-year.
Vikram Karnani, President and Chief Executive Officer
We generated a record $216.3 million in quarterly net revenue and $121.6 million in adjusted EBITDA, with our ADHD franchise now contributing more than 36% of total revenue.
Colleen Tupper, Chief Financial Officer
Not in the filing
stated, not guessed- Prior-quarter comparisons were not reported for the financial metrics or product revenues.
- GAAP gross margin and non-GAAP gross margin were not reported.
- Free cash flow was not reported.
- Cash from operations for the comparable prior-year quarter was not reported.
- A prior earnings-release outlook was not provided, so no comparison of actual results with prior guidance is available.
- A reconciliation of full-year 2026 adjusted EBITDA guidance to the most directly comparable forward-looking GAAP measure was not provided.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.